Central Nervous System
Insights on the major trends in aging disorders and pain conditions including the development of targeted therapies in clinical trial designs and patient care.
Expert opinions on innovative processes include protocol design, site training, and real time data quality analysis in central nervous systems.
Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
In this CNS whitepaper, which includes extracts from our survey of over 120 neurodegenerative therapeutic developers, we examine how innovative methodologies and technologies are being implemented to improve the success rate of clinical trials across a range of neurodegenerative disorders.
Clinical strategies to optimise software as a medical device (SaMD) for treating mental health
Mental health disorders affect millions, and with increasing diagnoses, the demand for new, accessible treatments is growing. In this whitepaper, we examine how SaMD, particularly through digital therapeutics, is providing new solutions for mental health management.
Therapeutic spotlight: Precision medicine considerations in rare diseases
In our latest therapeutic spotlight, ICON’s experts explore the evolving therapeutic landscape of precision medicine with a special focus on the unique application in ALS. We outline key considerations for developing patient-centric, streamlined precision medicine programs that promote patient engagement, improve protocol adherence and reduce dropout rates – ultimately accelerating the delivery of meaningful therapies to patients.
A mind for digital therapeutics: Considerations for DTx clinical trials in CNS indications
DTx deliver evidence-based therapeutic intervention using software to prevent, manage, or treat medical disorders or disease. Because of the evidence-based nature of DTx, in many cases a clinical trial is required to demonstrate safety and efficacy. However, since such therapeutics are relatively new, there are many aspects to these clinical trials that differ from trials for traditional therapeutics, and which sponsors will need to consider.
Traumatic brain injury trials
The manifestations and effects of TBI are varied and impact diverse populations. To improve prevention and therapy, we need to conduct further clinical research to evaluate and validate better strategies for diagnosis and disease characterisation. A better understanding of how TBI — mild and severe — manifests, can lead to better identification of biomarkers, and the development of prevention and treatment strategies.
Key considerations for Parkinson’s disease trials
While there are many advances in Parkinson’s Disease (PD), such as identification of new biomarkers to measure disease progression, valuable insights in study design coming from Alzheimer’s Disease trials, and creative approaches for patient recruitment, challenges still remain in this therapeutic area.
Key considerations in chronic pain clinical trials
There has been an increased prevalence of lifetime substance abuse, creating an urgent need for innovative pain medications without the use of opioids. Unfortunately, clinical development of non-opioid pain medications has been hindered by a massive placebo-response.In our whitepaper, we discuss the aspects of pain studies that sponsors will need to consider to ensure success of their chronic pain trial model.
Blogs and media articles insights in central nervous system and Alzheimer's disease
-
Media article: Shock to the System: An Examination of Neurostim Technologies
Learn how targeted electrical nerve stimulation technology can aid in chronic disease management by improving on current treatment methods in MPO Magazine's recent article.
-
Media article: Parkinson’s Disease Clinical Trials
An Outsourcing-Pharma article exploring Parkinson’s disease clinical trials, featuring commentary from ICON Central Nervous System (CNS) experts Dr Peter Schueler (Sr VP, Drug Development Services) and Haichen Yang (VP, Global Therapeutic Lead).
-
Media article: Special Report on Drug Delivery
An article featuring commentary from Peter Schueler, on the challenges of the blood-brain barrier (BBB) in CNS.
-
Blog: Digital therapeutics considerations for CNS
This blog explores DTx in CNS clinical trials: regulatory landscape, data management, endpoints, payer coverage, and future trends.
-
Blog: How to improve participation of asymptomatic patients in neurodegenerative disease registries
Insight into the power of patient-registries and how they can be used to increase participation of neurodegenerative patients.
-
Blog: Harnessing digital health to advance traumatic brain injury clinical trials
Advances in wearable technology have provided an effective tool to monitor outcomes and facilitate the delivery of interventions in patients across indications, especially those in need of rehabilitation interventions.
-
Blog: Bringing an invisible battle to the forefront: How to better design military-related TBI clinical trials
A form of acquired brain injury that occurs when trauma causes damage to the brain, TBI has become increasingly apparent in military personnel.
-
Blog: Measuring the Impact of Physical Activity and Exercise on Alzheimer’s Disease
There is considerable and increasing body of published research investigating the impact of physical activity and exercise has on Alzheimer’s disease.
Receive more insights on the central nervous system
Please visit ICON's Preference Centre and select 'CNS, Pain and Ageing related disorders' under 'Therapeutic Areas of Interest' to receive new insights on rare and orphans diseasesCNs, Pain and Ageing related disorders..
CNS, Pain and Ageing related disorders
ICON’s experience of CNS, Pain and Ageing related disorder studies comprises global and regional clinical research in all major areas of neurology, psychiatry and pain research, and all phases of clinical drug development. Read more about ICON's services.